Related Experiment Video
Updated: Sep 14, 2025
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective study
Jing Xue1,2,3, Zhihao Lian4, Xiaoyan Li1,2,3
1Department of Pharmacy, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Introduction:
Oxaliplatin (OXA) serves as a first-line treatment for digestive system tumors such as colorectal cancer (CRC) and gastric cancer. OXA-induced hypersensitivity reactions (HSRs) may pose life-threatening risks to patients. This study aimed to explore the risk factors and protective factors of OXA-induced HSRs in Chinese CRC patients.
Methods:
A retrospective analysis was conducted on 233 CRC patients who received OXA treatment between June 2022 and December 2022. Demographic data and medical histories were extracted from the hospital's medical record system.
Results:
Among the 233 patients, 51 patients (21.9%) developed OXA-induced HSRs, with the median treatment cycle at onset being the 4th cycle. Univariate and multivariate analyses revealed that an OXA treatment interruption lasting ≥30 days (P < 0.05, odds ratio [OR] = 10.76, 95% confidence interval [CI] = 4.57-25.3), a history of platinum-based drug allergy (P < 0.05, OR = 19.03, 95% CI = 1.66-217.99), and abnormal absolute neutrophil count (P < 0.05, OR = 8.96, 95% CI = 3.11-25.86) were independent risk factors. Pretreatment with dual-drug or triple-drug prophylactic regimens before OXA administration was identified as an independent protective factor (P < 0.05, OR = 0.37, 95% CI = 0.17-0.82). The area under the receiver operating characteristic (ROC) curve was 0.82 (P < 0.001, 95% CI = 0.75-0.89). Although previous platinum-based drug dosage and abnormal absolute lymphocyte count showed significant differences in univariate analysis, they did not emerge as independent influencing factors in multivariate logistic regression.
Conclusion:
Prolonged OXA treatment interruption, a history of platinum-based drug allergy, and abnormal neutrophil count are independent risk factors for OXA-induced HSRs, while dual/triple-drug pretreatment acts as an independent protective factor. Clinicians should evaluate these risks before medication and consider intensified pretreatment regimens to reduce HSR incidence.
More Related Videos
Related Concept Videos
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
01:19Factors Affecting Drug Distribution: Miscellaneous Factors
Age plays a significant role due to differences in body composition among different age groups. Infants, for instance, have a higher proportion of total body water and lower albumin levels, a protein that binds drugs in the bloodstream. This unique composition in infants enhances the...
01:21Factors Affecting Drug Response: Overview
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...